GLP-1s before surgery: what the current anesthesia guidance actually says

If you're on a GLP-1 and have surgery, a colonoscopy, or any procedure requiring sedation coming up, there's a genuine, evidence-based reason your care team may ask about your medication timing — and the guidance on exactly what to do has evolved since it first became a concern in 2023.

The underlying concern

GLP-1s slow gastric emptying by design — it's part of how they reduce appetite. Under general anesthesia or deep sedation, a stomach that hasn't fully emptied carries a small but real risk of aspiration: regurgitated stomach contents entering the airway while a patient's normal protective reflexes are suppressed. That risk is well understood in anesthesia generally and isn't unique to GLP-1s, but the drug's mechanism gave anesthesiologists a specific, plausible reason to ask about it starting in 2023, when the first case reports of retained gastric contents in GLP-1 users appeared.

What the current multi-society guidance says

The most current guidance is a 2024 multisociety clinical practice statement — representing anesthesiology, gastroenterology, and surgical societies together — that updated and superseded earlier single-society recommendations¹. Rather than a blanket rule to stop GLP-1s for a fixed number of days before any procedure, the guidance takes a risk-stratified approach: it weighs the specific drug, dose, and how recently it was started or adjusted, alongside whether the patient has GI symptoms like ongoing nausea, vomiting, or abdominal distension, which are a stronger individual predictor of retained stomach contents than simply being on the medication at all. A companion guidance document, representing surgical and endoscopic societies specifically, reinforced this same risk-based framework for perioperative and pre-procedure planning².

What a real-world study found

A multicenter cross-sectional study examined actual retained gastric contents on endoscopy in patients who had used a GLP-1 receptor agonist before the procedure and found that retained contents were, in fact, uncommon in this real-world population³ — a reassuring finding that complements the more cautious tone of the original 2023 guidance and helps explain why the field moved toward the more individualized, risk-stratified approach reflected in the current guidance rather than a uniform stop-the-drug-for-everyone rule.

What this means practically

The specific instructions you get — whether to hold a dose, for how long, and whether any dietary changes are needed beforehand — should come from your surgeon, anesthesiologist, or the facility performing your procedure, since they're applying the current risk-stratified framework to your specific situation, not a fixed universal rule. What's useful to do on your end: tell every provider involved in an upcoming procedure that you're on a GLP-1, when you last took it, and whether you've had any recent GI symptoms, even if nobody asks directly. This is exactly the kind of detail that's easy to omit if you don't realize it's relevant. If your prescriber does ask you to pause a dose, our dosing and titration guides cover how the schedule generally works, which can help you understand how a brief pause fits into your broader treatment timeline.

Why this belongs in your provider conversation, not just your surgeon's

It's worth raising an upcoming procedure with your GLP-1 prescriber too, not only your surgical team — coordinating dose timing across both is part of what a genuinely attentive provider does, and it's the kind of detail covered in a real intake process; see how to choose a GLP-1 provider for what that ongoing coordination should look like beyond the initial prescription.

The honest bottom line

The aspiration-risk concern behind GLP-1 perioperative guidance is real and well-reasoned, current multi-society guidance takes a more individualized, risk-stratified approach than the earlier blanket recommendations, and real-world endoscopy data suggests retained gastric contents are uncommon in practice. The practical step that matters most is simple: disclose your GLP-1 use and any GI symptoms to everyone involved in an upcoming procedure, and follow their specific instructions rather than a generic rule. This is educational information, not medical advice — your surgical and prescribing teams should set your specific plan.